An observational study in Kidney Tansplant, Secondary Hyperparathyroidism and Hyperparathyroidism, sponsored by Amgen. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2007-12-28.
Sponsored by Amgen · Observational
Retrospective chart review to gather information on Sensipar patterns of use and effects on biochemical parameters in renal transplant recipients
305 studies on the registry are indexed under Hyperparathyroidism; 23 are open to participants now.
This study's enrollment of 50 is below the median of 100 across 88 observational studies indexed under Hyperparathyroidism.
Browse Hyperparathyroidism studies →Amgen is the lead sponsor of 1,015 studies on the registry; 49 are open to participants now.
Of its 245 completed or terminated interventional studies of FDA-regulated products, 159 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
No study locations are listed for this record.
This study is completed, as verified in Dec 2007. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Amgen